Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw [Yahoo! Finance]
Nevro Corp. (NVRO)
Last nevro corp. earnings: 2/25 04:10 pm
Check Earnings Report
US:NYSE Investor Relations:
nevro.com/english/investors/overview/default.aspx
Company Research
Source: Yahoo! Finance
Feb. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the U.S. Food and Drug Administration (FDA) cleared its sacroiliac joint fusion device, which will be marketed as Nevro1, without the need to include the screw ("NevroFix™"). Nevro1, an integrated transfixing technology, is proven to immediately transfix the SI joint to allow the opportunity for long-term fusion. Self-contained, deployable titanium anchors transfix the sacrum and ilium to enhance axial and rotational stability of the joint. In addition, Nevro's proprietary instrumentation allows for optimal intra-articular SI joint preparation which is critical to achieve joint fusion. Nevro1 comes with 3D-printed, bone-growth enhancing technology which helps promote bone cell growth and, as a result, fusion. "Nevro1 as a standalone device represents the most significant advancement in SI f
Show less
Read more
Impact Snapshot
Event Time:
NVRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVRO alerts
High impacting Nevro Corp. news events
Weekly update
A roundup of the hottest topics
NVRO
News
- Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024PR Newswire
- Nevro Corp. (NYSE: NVRO) had its price target lowered by analysts at Royal Bank of Canada from $18.00 to $16.00. They now have a "sector perform" rating on the stock.MarketBeat
- Nevro Corp. (NYSE: NVRO) had its price target lowered by analysts at Mizuho from $20.00 to $16.00. They now have a "neutral" rating on the stock.MarketBeat
- Nevro Corp. (NYSE: NVRO) had its price target lowered by analysts at Wells Fargo & Company from $17.00 to $14.00. They now have an "equal weight" rating on the stock.MarketBeat
- Nevro Corp. (NYSE: NVRO) had its price target lowered by analysts at Citigroup Inc. from $18.00 to $16.00. They now have a "neutral" rating on the stock.MarketBeat
NVRO
Earnings
- 2/21/24 - Beat
NVRO
Sec Filings
- 4/26/24 - Form 4
- 4/25/24 - Form 8-K
- 4/15/24 - Form 4
- NVRO's page on the SEC website